MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Olfactory dysfunction"

  • 2025 International Congress

    Utility of Digital Olfactory Assessment (Sensify) in Parkinson’s Disease: Preliminary Findings from the IPDGC Africa in Egypt

    N. Shebl, S. Mondal, F. Waheed, A. Farag, N. Abonar, M. Abdelhady, S. Asran, M. Salama, M. Rizig (Cairo, Egypt)

    Objective: Validate a digital olfactory assessment for Parkinson’s disease (PD) in Egyptian participants by comparing olfactory performance in PD patients, healthy controls, and those with…
  • 2025 International Congress

    Identifying subjects at high risk for prodromal Parkinson’s Disease using dopamine transporter imaging deficit in a step-wise recruitment strategy: Data of Healthy Brain Ageing (HeBA)

    S. Schade, C. Corinne, S. Ghosh, A. Garrido, E. Lang, P. Mahlknecht, C. Pauly, D. Pilco, R. Rautenkranz, K. Rege, S. Scaglione, S. Schnell, T. Wicke, V. Satagopam, M. Marti, E. Tolosa, W. Poewe, R. Krüger, C. Trenkwalder, B. Mollenhauer (Kassel, Germany)

    Objective: To optimize screening for subjects with dopamine transporter (DaT) imaging deficit being at high risk for prodromal Parkinson's disease (PD). Background: Efficient screening methods…
  • 2025 International Congress

    Alpha-Synuclein Aggregates in the Olfactory Epithelium of Subjects with Parkinson Disease, Dementia, COVID-19, and in Aged Controls

    J. Tomlinson, N. Lengacher, A-K. Jochum, J. Franz, L. Flatz, B. Mollenhauer, C. Stadelmann, J. Woulfe, M. Schlossmacher (Ottawa, Canada)

    Objective: We sought to examine whether neuroepithelial structures of the nasal cavity differ between individuals diagnosed with a Lewy body disorder vs those with COVID19…
  • 2025 International Congress

    PREDIGT 2.0: A Self-Administered, Two-Step Screening Tool to Identify Individuals with Parkinson’s Disease

    J. Li, K. Grimes, J. Saade, N. Mauri, J. Tomlinson, A. Frank, D. Manuel, B. Mollenhauer, M. Schlossmacher (Ottawa, Canada)

    Objective: To pilot the 2-step PREDIGT Score model for feasibility and improve it by simplifying both steps. Background: We previously demonstrated that the original PREDIGT…
  • 2025 International Congress

    16-years of Evaluations for Prodromal Parkinson Features in an At-Risk Cohort with Gaucher Disease

    E. Sidransky, E. Ryan, S. Nishimura, N. Tayebi, G. Lopez (Bethesda, MD, USA)

    Objective: To evaluate prodromal features of Parkinson disease in a cohort of "at-risk"  Gaucher patients and GBA1 carriers . Background: Variants in GBA1 mutations are…
  • 2025 International Congress

    Olfactory-Trigeminal Interactions in Parkinson’s Disease Compared to Other Olfactory Disorders

    S. Brosse, O. Fortier-Lebel, E. Hudon, K. Lapointe, C. Tremblay, J. Frasnelli (Trois-Rivières, Canada)

    Objective: To investigate the interaction between the olfactory and trigeminal systems in Parkinson’s disease (PD) as opposed to other forms of olfactory dysfunction and controls…
  • 2024 International Congress

    First in vivo evidence of the role of the noradrenergic system in olfactory dysfunction in Parkinson’s disease

    C. Laurencin, S. Lancelot, S. Brosse, J. Redouté, I. Mérida, D. Le Bars, N. Costes, S. Thobois, P. Boulinguez, B. Ballanger (lyon, France)

    Objective: To investigate the relationship between in vivo noradrenergic markers and olfactory impairment in patients with Parkinson’s disease (PD). Background: Degeneration of the noradrenergic (NA)…
  • 2024 International Congress

    Understanding the earliest phases of Parkinson’s disease (PD) – an expanding opportunity to study ‘at-risk’/early/prodromal PD in the Global Parkinson’s Genetics Program (GP2)

    K. Atterling Brolin, S. Jasaityte, M. Teferra, M. Rezaei, L. Jones, J. Trinh, E. Stafford, M. Makarious, M T. Periñan, L. Lange, S. Waters, A. Martinez Carrasco, M. Tan, H. Iwaki, H. Morris, C. Blauwendraat, A. Singleton, Z. Gan-Or, A. Noyce (Lund, Sweden)

    Objective: To identify and recruit at-risk/early/prodromal Parkinson’s disease (PD) cohorts around the world to the Global Parkinson’s Genetics Program (GP2, http://gp2.org/) and build a global…
  • 2024 International Congress

    Bidirectional Relationship Between Olfaction and Parkinson’s Disease

    J. Kim, S. Bandres-Ciga, K. Heilbron, 23. INC., C. Blauwendraat, A. Noyce (London, United Kingdom)

    Objective: To establish a causal direction and genetic relationship between olfactory function and Parkinson’s disease (PD). Background: Degradation in olfactory function or hyposmia is a…
  • 2024 International Congress

    Integrating Non-Motor Symptoms and Gender Variability in Machine Learning for Early Parkinson’s Disease Detection

    MZA. Ali, PSD. Dholaniya (Hyderabad, India)

    Objective: Our study aimed to develop a machine learning (ML) model for the early detection of Parkinson's disease (PD), utilizing non-motor symptoms (NMS) and DNA…
  • 1
  • 2
  • 3
  • …
  • 15
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley